Table 2.

Vaccine effectiveness against COVID-19 infection by vaccine type and duration since full vaccination

		‘Late' (Fully Vaccinated in July to August)					‘Early' (Fully Vaccinated in April to June)
		Total	Person-days at risk	Incidence rates/1,000 persons	VE	CI (95%)	Total	Person-days at risk	Incidence rates/1,000 persons	VE	CI (95%)
	COVID-19 Infection
Overall	Unvaccinated	81,987	46,811,305	1.751	ref	ref	81,987	46,811,305	1.751	ref	ref
	BNT162b2	30,070	136,056,979	0.221	90.8	89.4, 92.1	21,888	41,756,536	0.524	79.3	76.1, 82.1
	CoronaVac	104,747	141,155,066	0.742	74.5	70.6, 78.0	6,039	3,843,839	1.571	30.4	18.8, 40.3
Age Group (in years)
15 to 39	Unvaccinated	. .	. .	. .	ref	ref	. .	. .	. .	ref	ref
	BNT162b2	. .	. .	. .	91.9	90.2, 93.3	. .	. .	. .	86.1	83.2, 88.5
	CoronaVac	. .	. .	. .	73.9	68.4, 78.5	. .	. .	. .	67.3	60.1, 73.3
40 to 59	Unvaccinated	. .	. .	. .	ref	ref	. .	. .	. .	ref	ref
	BNT162b2	. .	. .	. .	88.9	86.5, 90.9	. .	. .	. .	77.3	72.3, 81.3
	CoronaVac	. .	. .	. .	70.5	64.1, 75.7	. .	. .	. .	32.4	16.7, 45.2
≥60	Unvaccinated	. .	. .	. .	ref	ref	. .	..	..	ref	ref
	BNT162b2	. .	. .	. .	90.9	89.1, 92.4	. .	. .	. .	69.8	63.7, 74.9
	CoronaVac	. .	. .	. .	78.6	74.4, 82.2	. .	. .	. .	-38.6	-68.4, -14.1

Abbreviations: CI, confidence intervals; COVID-19, coronavirus disease; VE, vaccine effectiveness; BNT162b2, Pfizer-BioNTech; CoronaVac, Sinovac.

The estimates were adjusted for age, gender and states of residence

The analysis compared between the ‘Late’ group, individuals vaccinated in July–August 2021 (1 to 2 months after vaccination during the outcomes observation period in September 2021), and the ‘Early’ group, individuals vaccinated in April–June 2021 (3–5 months after vaccination), and unvaccinated individuals by August 31^st, 2021, who act as the baseline